Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Considerations in analyzing single-trough concentrations using mixed-effects modeling.

Brian P Booth1, Jogarao V S Gobburu

  • 1US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Clinical Pharmacology and Biopharmaceutics, Rockville, MD 20857, USA.

Journal of Clinical Pharmacology
|November 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Precision to Personalized: Catalyzing AI-Enabled Innovation in Drug Development.

Clinical and translational science·2026
Same author

A Large Cohort Study to Identify Risk Factors of Acute Kidney Injury in Pediatric Patients Undergoing Intravenous Vancomycin Therapy.

Pharmacotherapy·2025
Same author

Evaluating Tranexamic Acid Dosing Strategies for Postpartum Hemorrhage: A Population Pharmacokinetic Approach in Pregnant Individuals.

Journal of clinical pharmacology·2025
Same author

Exploration of the potential impact of batch-to-batch variability on the establishment of pharmacokinetic bioequivalence for inhalation powder drug products.

CPT: pharmacometrics & systems pharmacology·2024
Same author

In memory of Dr. Thomas M. Ludden: a pioneer in pharmacometrics, a mentor to many, and a legacy of compassionate science.

Journal of pharmacokinetics and pharmacodynamics·2024
Same author

Perinatal Caffeine Administration Improves Outcomes in an Ovine Model of Neonatal Hypoxia-Ischemia.

Stroke·2024
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
Same journal

New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

Journal of clinical pharmacology·2026
Same journal

Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

Journal of clinical pharmacology·2026
Same journal

The Journal of Clinical Pharmacology: 65 Years of History.

Journal of clinical pharmacology·2026
Same journal

Decoupling CAR-T Expansion, Conversion, and Decay Timing: Physiologically Aligned Semi-Mechanistic Modeling With Smooth Gating and a Cauchy Likelihood Residual Model.

Journal of clinical pharmacology·2026
Same journal

Mind the Gap: Unraveling the Pharmacokinetic Variability of Δ9-Tetrahydrocannabinol (THC).

Journal of clinical pharmacology·2026
See all related articles

Trial design significantly impacts pharmacokinetic parameter estimation. Sparse, single-trough sampling introduces bias, while dense data and advanced methods like FOCE improve accuracy.

Area of Science:

  • Pharmacokinetics
  • Pharmacometric modeling
  • Clinical trial design

Background:

  • Accurate pharmacokinetic (PK) parameter estimation is crucial for drug development and dosing.
  • Trial design and data analysis choices can introduce bias and affect the precision of PK estimates.
  • Understanding these effects is essential for reliable drug modeling.

Purpose of the Study:

  • To evaluate how different trial designs and data analysis strategies influence the bias and precision of pharmacokinetic parameter estimation.
  • To compare the performance of dense versus sparse sampling schemes in PK modeling.
  • To assess the impact of various estimation methods on PK parameter accuracy.

Main Methods:

  • Simulations and analyses were performed using NONMEM software.

Related Experiment Videos

  • A one-compartment open model with intravenous administration was utilized.
  • Plasma concentrations were simulated under dense (five samples) and sparse (single-trough) sampling conditions.
  • Different parameter estimation strategies were explored, including fixing parameters and using first-order conditional estimation (FOCE) and first-order (FO) methods.

    • Main Results:

    • Single-trough data alone resulted in significant bias (17%) in clearance (CL) estimates, contrasted with minimal bias (<1%) from dense data.
    • Estimating only the mean and variance of CL improved accuracy, with bias ranging from -11% to 1.4%.
    • Incorporating dense data further enhanced CL estimates, reducing bias to -2.3% to 0.3%.
    • FOCE methods yielded superior CL estimates compared to FO methods, particularly when using dense data.
    • Bayesian estimation methods also showed improvement with these strategies.

    Conclusions:

    • Avoid single-trough sampling for PK studies unless prior drug knowledge is substantial.
    • When single-trough data is unavoidable, refrain from estimating all PK parameters.
    • Leverage prior information by integrating single-trough data with dense data from other studies.
    • Employ Bayesian estimates when the PK model and parameters are well-established.